Cartoon illustration. Inside a cozy cell kitchen, a friendly chef-hat kitchen robot stands between two kinds of recipe cards and wonders which to use. On a corkboard, a handwritten custom-order card for a patient named Maya lists her own tumor typos as colored beads. On the counter sits a neat printed stack of house-special cards. Outside the door, a smiling courier carries an mRNA card in a ring of pink fat bubbles, and a small immune cell waits nearby.
One card written for one person, or one recipe printed for many. Illustration: cells.com.

Journal · Aging & cells

mRNA Cancer Vaccines: Custom Order or House Special?

Nov 4, 2026 · Aging & cells · 1 min read

The same recipe-card trick, aimed at cancer instead of a germ.

Yesterday we saw how an mRNA vaccine hands your cells a wanted poster for a virus. Can it work for cancer?

Cancer cells carry typos in their DNA. Some typos make odd proteins called neoantigens (NEE-oh-AN-tih-jenz) that the immune system could learn to spot.1

Two panels joined by the word or. Left, Custom order: a handwritten recipe card pinned to a corkboard reads Custom order, for: Maya, with a row of colored beads marking her tumor typos. Right, House special: a tidy printed stack of cards labeled House Special, serves many.
A card written for one person, or a recipe printed for many. Illustration: cells.com.

Custom order. Scientists read one person’s tumor, pick its typos, and write a recipe card just for them. In a mid-size melanoma trial, adding a personalized mRNA vaccine to immunotherapy was linked to fewer cancers returning compared with immunotherapy alone.2 A small pancreatic cancer study saw strong immune responses in about half of patients.3

House special. Other vaccines target proteins many tumors share, so one recipe could fit many people without being made one at a time.1

Both are still being tested. Next week, we dig deeper.

References

  1. Lorentzen CL, Haanen JB, Met Ö, Svane IM. “Clinical advances and ongoing trials on mRNA vaccines for cancer treatment.” Lancet Oncology 23:e450–e458 (2022). https://doi.org/10.1016/S1470-2045(22)00372-2
  2. Weber JS et al. “Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.” The Lancet 403:632–644 (2024). https://doi.org/10.1016/S0140-6736(23)02268-7
  3. Rojas LA et al. “Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.” Nature 618:144–150 (2023). https://doi.org/10.1038/s41586-023-06063-y

What this is not. Education only. Stories on cells.com are not medical advice. cells.com does not diagnose, treat, prescribe, run laboratory tests, or ship kits.

More in Journal

Simon Ng · Founder, cells.com

Simon Ng is the founder of cells.com. He has spent more than a decade on biotech finance executive teams, including at Quark Pharmaceuticals and Adverum Biosciences, and holds an MBA.